Search results
Found 460 matches for
RA Capital Management leads $45M Series A financing for PepGen’s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases. PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round.
Orfonyx Bio – big ambitions in protein upregulation
9 April 2025
Orfonyx Bio is looking to make its mark as a leader in protein upregulation for clinical benefit – and has made technical progress towards this goal over the past two years. In that time as a BioEscalator tenant the University of Oxford spin-out has also grown from two to seven employees, raised an Oxford Science Enterprises-backed seed round and started to understand where its approach might have the greatest clinical impact. Now it’s raising additional funding.
Infinitopes granted Phase I/IIa Clinical Trial Application approval to evaluate precision vaccine targeting early-stage oesophageal cancer
8 April 2025
Oxford, UK – 9 April 2025 – Infinitopes Ltd today announces that the UK Medicines and Healthcare products RegulatoryAgency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-humanPhase I/IIa clinical trial of ITOP1, the company’s lead ‘off-the-shelf’ cancer vaccine.
Care Fertility and U-Ploid Biotechnologies announce research collaboration to improve egg quality in women of advanced maternal age
7 April 2025
Care Fertility, a leading fertility treatment provider, and U-Ploid Biotechnologies, a pioneering reproductive health biotech, today announces a research collaboration aimed at improving egg quality and improve fertility treatment.
PepGen announces appointment of two new directors to its Board
30 March 2025
The company announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors.
Moa named one of TIME's top greentech companies in 2025
26 March 2025
Moa recognised as leading global innovator in environmental impact.
Moa forms new biological partnership with NAICONS
25 March 2025
Oxford-based agricultural biotech firm Moa Technology has stepped up the global hunt for a safe, effective and affordable biological herbicide by forming a new partnership with NAICONS, an Italian natural products company.
Infinitopes strengthens Board with two biotech leaders to advance precision immunotherapies into the clinic
20 March 2025
Infinitopes welcomes Jo Brewer, PhD (CSO at Adaptimmune), and Dan Menichella (former CEO and CBO of CureVac's US subsidiary) as incoming Non-Executive Directors, bringing deep expertise in immunotherpay and oncology innovation.
The Gender Advantage: Building Inclusive and Thriving Ventures
20 March 2025
To celebrate International Women's Day 2025, the BioEscalator was delighted to host a double panel discussion and networking event with EnSpire Oxford and Advanced Oxford.
Entelo Bio ushering in new ways of doing science
12 March 2025
Entelo Bio, a venture backed biotechnology company pioneering the emerging isoform frontier of medicine, releases Flow Agent, an adaptive agentic (autonomous, AI-driven) based workflow management framework for bioinformatics workflows.
BioEscalator Bulletin - Spring 2025
11 March 2025
Stay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Spring 2025 edition of the BioEscalator Bulletin.
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
26 February 2025
Oxford, United Kingdom – 26 February 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Board as a non-executive director.
OXcan President and Co-Founder features as guest speaker on TheHill Digital Innovation Podcast
19 February 2025
Andreas Halner, president and co-founder of Oxford Cancer Analytics (OXcan), who chats to our director, Megan Morys-Carter, about the company's inception, what makes the technology so revolutionary and the ever increasing success OXcan have been met with recently.
Enara Bio embarks on a research collaboration with George Washington University to deepen understanding of Dark Antigen® biology and expression
18 February 2025
Collaboration may inform future combination strategies that can maximise the efficacy of Enara Bio’s pipeline of TCR-based immunotherapies targeting Dark Antigens®
New ‘Super Test’ for prostate cancer developed in the UK by EDX Medical
17 February 2025
CAMBRIDGE, England--(BUSINESS WIRE)--Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients.
BioEscalator Bulletin – Annual Review 2023/24 launched
29 January 2025
The BioEscalator is delighted to have launched its inaugural Annual Review, ‘Driving innovation, advancing human health ’. It provides for the first time a discussion of our achievements in 2023/24, plus the milestones from our initial five years of operation.
Enara Bio listed in the inaugural edition of The Sunday Times 100 Tech 2025
22 January 2025
The guide showcases Britain's fastest-growing private tech companies from The Sunday Times, commercialising innovation across the UK. "This recognition is a testament to our innovative science and the hard work of our incredible team as we strive to develop safe and effective treatments for cancer patients." Enara Bio
U-Ploid Biotechnologies announces the appointment of Professor Alison Campbell to its advisory board
15 January 2025
U-Ploid, a venture-backed biotechnology company developing next-generation fertility therapeutics, is pleased to announce the appointment of Professor Alison Campbell to its Advisory Board. In this key role, Professor Campbell will provide strategic guidance on company research programmes, working closely with the U-Ploid team to drive innovation in fertility treatments.
Oxford Cancer Analytics raises USD$11M in series A funding to transform early lung cancer detection and enable curative treatments
9 January 2025
Dr. Heinrich Roder, expert in lung cancer proteomics liquid biopsy, appointed as Senior Vice President of Research and Development at OXcan.
Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
9 January 2025
The agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.
Theolytics appoints David Apelian MD, PhD, MBA as CEO
17 December 2024
David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer.